Aldeyra Therapeutics, Inc.ALDXNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-36.15%
↓ 582% below average
Average (39q)
7.50%
Historical baseline
Range
High:142.09%
Low:-49.26%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -36.15% |
| Q2 2025 | 14.57% |
| Q1 2025 | -49.26% |
| Q4 2024 | 17.59% |
| Q3 2024 | -16.89% |
| Q2 2024 | 142.09% |
| Q1 2024 | 43.86% |
| Q4 2023 | -38.26% |
| Q3 2023 | -0.02% |
| Q2 2023 | -38.03% |
| Q1 2023 | 25.38% |
| Q4 2022 | -22.34% |
| Q3 2022 | -20.80% |
| Q2 2022 | 19.10% |
| Q1 2022 | -4.73% |
| Q4 2021 | -0.41% |
| Q3 2021 | 12.37% |
| Q2 2021 | 48.51% |
| Q1 2021 | 9.93% |
| Q4 2020 | 14.59% |
| Q3 2020 | 25.54% |
| Q2 2020 | -26.35% |
| Q1 2020 | -31.00% |
| Q4 2019 | -40.74% |
| Q3 2019 | 52.12% |
| Q2 2019 | 35.88% |
| Q1 2019 | -8.19% |
| Q4 2018 | 8.48% |
| Q3 2018 | 16.02% |
| Q2 2018 | 2.92% |
| Q1 2018 | 19.03% |
| Q4 2017 | 56.68% |
| Q3 2017 | -8.05% |
| Q2 2017 | 14.25% |
| Q1 2017 | -2.26% |
| Q4 2016 | 1.98% |
| Q3 2016 | 19.22% |
| Q2 2016 | -19.25% |
| Q1 2016 | 12.82% |
| Q4 2015 | 49.90% |